From: PALB2 variants in hereditary and unselected Finnish Prostate cancer cases
Patient | Cancer | Histology | Age at diagnosis | Reason for diagnosis | First treatment | Primary PSA value | WHO grading | Gleason grading | TNM grading | IHC |
---|---|---|---|---|---|---|---|---|---|---|
6 | Prostate | Adenocarcinoma | 83 | NA | NA | NA | NA | NA | NA | Â |
11 | Prostate | Adenocarcinoma | 68 | Symptoms | Orchiectomy | NA | III | Na | T3NXMX | Â |
13 | Stomach | Adenocarcinoma | 70 | Symptoms | Gastrectomy | NA | NA | Na | T4N0 M0 | Â |
13 | Skin | Carcinoma epidermoides | 75 | NA | Resection | NA | NA | Na | NA | Â |
13 | Prostate | Adenocarcinoma | 76 | Elevated PSA | Orchiectomy | 47 | III | 2+3 = 5 | T2NXMX | Â |
15 | Prostate | Adenocarcinoma | 69 | Elevated PSA | Brakytherapy | 7.7 | I | 2+3 = 5 | T1cNXMX | Â |
17 | Breast | Ductal carcinoma | 52 | Screening mammography | Mammary resection | NA | I | Na | T1N0 M0 | ER+, PR+ |
24 | Breast | Ductal carcinoma | 49 | Mammography | Mammary resection | NA | I | Na | T1N0 M0 | NA |